HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Immunotherapy for Colorectal Cancer: A Review of Current and Novel Therapeutic Approaches.

Abstract
Colorectal cancer (CRC) remains a leading cause of cancer-related deaths in the United States. Although immunotherapy has dramatically changed the landscape of treatment for many advanced cancers, the benefit in CRC has thus far been limited to patients with microsatellite instability high (MSI-H):DNA mismatch repair-deficient (dMMR) tumors. Recent studies in the refractory CRC setting have led to US Food and Drug Administration approvals for pembrolizumab as well as nivolumab (with or without ipilimumab) for tumors harboring an MSI-H:dMMR molecular profile. Several randomized controlled trials are underway to move immunotherapy into the frontline for metastatic cancer (with or without chemotherapy) and the adjuvant setting. Awareness of these studies is critical given the relatively low incidence (approximately 3%-5%) of MSI-H:dMMR in advanced or metastatic CRC to support study completion, because the results could be potentially practice changing. The real challenge in this disease is related to demonstrating the benefit of immunotherapy for the vast majority of patients with CRC not harboring MSI-H:dMMR. Given the rapid pace of scientific changes, this article provides a narrative review regarding the current landscape of immunotherapy for CRC. Particular attention is paid to the currently available data that inform today's clinical practice along with upcoming randomized controlled trials that may soon dramatically change the treatment landscape for CRC.
AuthorsAaron J Franke, William Paul Skelton, Jason S Starr, Hiral Parekh, James J Lee, Michael J Overman, Carmen Allegra, Thomas J George
JournalJournal of the National Cancer Institute (J Natl Cancer Inst) Vol. 111 Issue 11 Pg. 1131-1141 (11 01 2019) ISSN: 1460-2105 [Electronic] United States
PMID31322663 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Copyright© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For permissions, please email: [email protected].
Chemical References
  • Antineoplastic Agents, Immunological
Topics
  • Antineoplastic Agents, Immunological (therapeutic use)
  • Colorectal Neoplasms (drug therapy, immunology)
  • Humans
  • Immunotherapy (methods)
  • Molecular Targeted Therapy
  • Prognosis

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: